Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 May;95(5):2067–2075. doi: 10.1172/JCI117893

Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C.

G Ballardini 1, P Groff 1, P Pontisso 1, F Giostra 1, R Francesconi 1, M Lenzi 1, D Zauli 1, A Alberti 1, F B Bianchi 1
PMCID: PMC295796  PMID: 7738174

Abstract

To obtain information on the mechanisms of hepatocellular damage and the determinants of response to interferon, hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C and intercellular adhesion-1 molecules, and the number of lobular T lymphocytes were studied in 38 anti-HCV-positive patients. 14 patients did not show a primary response to interferon treatment. HCV genotype 1b was detected in 11 of them. They displayed higher scores of HCV-positive hepatocytes, HLA-A,B,C, and ICAM-1 molecules expression than with the responders. HCV-infected hepatocytes maintained the capacity to express HLA-A,B,C and ICAM-1 molecules. CD8-positive T cells in contact with infected hepatocytes and Councilman-like bodies were observed. A significant correlation was found between the number of lobular CD8-positive T cells and alanine amino transferase levels. No differences were observed in clinical, biochemical, and histological features between patients with high and low number of hepatocytes containing HCV antigens. These data suggest a prominent role of T cell-mediated cytotoxicity in the genesis of hepatocellular damage. The high expression of interferon-inducible antigens like HLA-A,B,C molecules suggests the presence of strong activation of the interferon system possibly related to high HCV replication in nonresponder patients infected with genotype 1b.

Full text

PDF

Images in this article

2071Image
on p.2071
2071Image
on p.2071
2071Image
on p.2071
2068Image
on p.2068
2072Image
on p.2072
2072Image
on p.2072
2073Image
on p.2073
2074Image
on p.2074
2074Image
on p.2074

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballardini G., Groff P., Giostra F., Francesconi R., Zauli D., Bianchi G., Lenzi M., Cassani F., Bianchi F. Hepatocellular expression of HLA-A, B, C molecules predicts primary response to interferon in patients with chronic hepatitis C. Am J Clin Pathol. 1994 Dec;102(6):746–751. doi: 10.1093/ajcp/102.6.746. [DOI] [PubMed] [Google Scholar]
  2. Battezzati P. M., Podda M., Bruno S., Zuin M., Crosignani A., Camisasca M., Chiesa A., Petroni M. L., Russo A., Gallotti P. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. Ital J Gastroenterol. 1992 Nov-Dec;24(9):481–484. [PubMed] [Google Scholar]
  3. Botarelli P., Brunetto M. R., Minutello M. A., Calvo P., Unutmaz D., Weiner A. J., Choo Q. L., Shuster J. R., Kuo G., Bonino F. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 1993 Feb;104(2):580–587. doi: 10.1016/0016-5085(93)90430-k. [DOI] [PubMed] [Google Scholar]
  4. Burgert H. G., Maryanski J. L., Kvist S. "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1356–1360. doi: 10.1073/pnas.84.5.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bursch W., Paffe S., Putz B., Barthel G., Schulte-Hermann R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis. 1990 May;11(5):847–853. doi: 10.1093/carcin/11.5.847. [DOI] [PubMed] [Google Scholar]
  6. CLARK H. F., SHEPARD C. C. A DIALYSIS TECHNIQUE FOR PREPARING FLUORESCENT ANTIBODY. Virology. 1963 Aug;20:642–644. doi: 10.1016/0042-6822(63)90292-7. [DOI] [PubMed] [Google Scholar]
  7. Calmus Y., Arvieux C., Gane P., Boucher E., Nordlinger B., Rouger P., Poupon R. Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology. 1992 Apr;102(4 Pt 1):1371–1377. [PubMed] [Google Scholar]
  8. Chayama K., Saitoh S., Arase Y., Ikeda K., Matsumoto T., Sakai Y., Kobayashi M., Unakami M., Morinaga T., Kumada H. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology. 1991 Jun;13(6):1040–1043. [PubMed] [Google Scholar]
  9. Chemello L., Alberti A., Rose K., Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med. 1994 Jan 13;330(2):143–143. doi: 10.1056/NEJM199401133300215. [DOI] [PubMed] [Google Scholar]
  10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  11. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  12. Di Bisceglie A. M., Hoofnagle J. H., Krawczynski K. Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology. 1993 Sep;105(3):858–862. doi: 10.1016/0016-5085(93)90905-r. [DOI] [PubMed] [Google Scholar]
  13. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  14. Dusheiko G., Schmilovitz-Weiss H., Brown D., McOmish F., Yap P. L., Sherlock S., McIntyre N., Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994 Jan;19(1):13–18. [PubMed] [Google Scholar]
  15. Ferrari C., Valli A., Galati L., Penna A., Scaccaglia P., Giuberti T., Schianchi C., Missale G., Marin M. G., Fiaccadori F. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology. 1994 Feb;19(2):286–295. [PubMed] [Google Scholar]
  16. Franco A., Barnaba V., Natali P., Balsano C., Musca A., Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology. 1988 May-Jun;8(3):449–454. doi: 10.1002/hep.1840080302. [DOI] [PubMed] [Google Scholar]
  17. Garson J. A., Lenzi M., Ring C., Cassani F., Ballardini G., Briggs M., Tedder R. S., Bianchi F. B. Hepatitis C viraemia in adults with type 2 autoimmune hepatitis. J Med Virol. 1991 Aug;34(4):223–226. doi: 10.1002/jmv.1890340405. [DOI] [PubMed] [Google Scholar]
  18. Gregory C. D., Murray R. J., Edwards C. F., Rickinson A. B. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988 Jun 1;167(6):1811–1824. doi: 10.1084/jem.167.6.1811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hagiwara H., Hayashi N., Mita E., Takehara T., Kasahara A., Fusamoto H., Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993 Mar;104(3):877–883. doi: 10.1016/0016-5085(93)91025-d. [DOI] [PubMed] [Google Scholar]
  20. Hayata T., Nakano Y., Yoshizawa K., Sodeyama T., Kiyosawa K. Effects of interferon on intrahepatic human leukocyte antigens and lymphocyte subsets in patients with chronic hepatitis B and C. Hepatology. 1991 Jun;13(6):1022–1028. [PubMed] [Google Scholar]
  21. Howcroft T. K., Strebel K., Martin M. A., Singer D. S. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science. 1993 May 28;260(5112):1320–1322. doi: 10.1126/science.8493575. [DOI] [PubMed] [Google Scholar]
  22. Kato T., Esumi M., Yamashita S., Abe K., Shikata T. Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus. Virology. 1992 Oct;190(2):856–860. doi: 10.1016/0042-6822(92)90925-f. [DOI] [PubMed] [Google Scholar]
  23. Koup R. A. Virus escape from CTL recognition. J Exp Med. 1994 Sep 1;180(3):779–782. doi: 10.1084/jem.180.3.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Koziel M. J., Dudley D., Wong J. T., Dienstag J., Houghton M., Ralston R., Walker B. D. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol. 1992 Nov 15;149(10):3339–3344. [PubMed] [Google Scholar]
  25. Krawczynski K., Beach M. J., Bradley D. W., Kuo G., di Bisceglie A. M., Houghton M., Reyes G. R., Kim J. P., Choo Q. L., Alter M. J. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. Gastroenterology. 1992 Aug;103(2):622–629. doi: 10.1016/0016-5085(92)90856-t. [DOI] [PubMed] [Google Scholar]
  26. Kwok S., Higuchi R. Avoiding false positives with PCR. Nature. 1989 May 18;339(6221):237–238. doi: 10.1038/339237a0. [DOI] [PubMed] [Google Scholar]
  27. Lau J. Y., Davis G. L., Kniffen J., Qian K. P., Urdea M. S., Chan C. S., Mizokami M., Neuwald P. D., Wilber J. C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993 Jun 12;341(8859):1501–1504. doi: 10.1016/0140-6736(93)90635-t. [DOI] [PubMed] [Google Scholar]
  28. Magrin S., Craxi A., Fabiano C., Simonetti R. G., Fiorentino G., Marino L., Diquattro O., Di Marco V., Loiacono O., Volpes R. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology. 1994 Feb;19(2):273–279. [PubMed] [Google Scholar]
  29. Montano L., Miescher G. C., Goodall A. H., Wiedmann K. H., Janossy G., Thomas H. C. Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology. 1982 Sep-Oct;2(5):557–561. doi: 10.1002/hep.1840020508. [DOI] [PubMed] [Google Scholar]
  30. Pignatelli M., Waters J., Brown D., Lever A., Iwarson S., Schaff Z., Gerety R., Thomas H. C. HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology. 1986 May-Jun;6(3):349–353. doi: 10.1002/hep.1840060303. [DOI] [PubMed] [Google Scholar]
  31. Sansonno D., Cornacchiulo V., Gatti P., Dammacco F. Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during beta-interferon therapy of hepatitis C virus-associated chronic active liver disease. Int J Clin Lab Res. 1992;22(2):100–105. doi: 10.1007/BF02591405. [DOI] [PubMed] [Google Scholar]
  32. Simmonds P., Holmes E. C., Cha T. A., Chan S. W., McOmish F., Irvine B., Beall E., Yap P. L., Kolberg J., Urdea M. S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol. 1993 Nov;74(Pt 11):2391–2399. doi: 10.1099/0022-1317-74-11-2391. [DOI] [PubMed] [Google Scholar]
  33. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993 Jun;74(Pt 6):1093–1102. doi: 10.1099/0022-1317-74-6-1093. [DOI] [PubMed] [Google Scholar]
  34. Takada N., Takase S., Enomoto N., Takada A., Date T. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol. 1992 Jan;14(1):35–40. doi: 10.1016/0168-8278(92)90128-c. [DOI] [PubMed] [Google Scholar]
  35. Takehara T., Hayashi N., Katayama K., Ueda K., Towata T., Kasahara A., Fusamoto H., Kamada T. Enhanced expression of HLA class I by inhibited replication of hepatitis B virus. J Hepatol. 1992 Mar;14(2-3):232–236. doi: 10.1016/0168-8278(92)90163-j. [DOI] [PubMed] [Google Scholar]
  36. Tsutsumi M., Urashima S., Takada A., Date T., Tanaka Y. Detection of antigens related to hepatitis C virus RNA encoding the NS5 region in the livers of patients with chronic type C hepatitis. Hepatology. 1994 Feb;19(2):265–272. [PubMed] [Google Scholar]
  37. Unutmaz D., Pileri P., Abrignani S. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J Exp Med. 1994 Sep 1;180(3):1159–1164. doi: 10.1084/jem.180.3.1159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., Takayanagi M., Higashi Y., Shibata M., Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology. 1992 Aug;16(2):293–299. doi: 10.1002/hep.1840160203. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES